Back to search

Article

Neratinib (N) with or Without Temsirolimus (Tem) in Patients (Pts) with Non-Small Cell Lung Cancer (Nsclc) Carrying Her2 Somatic Mutations: an International Randomized Phase Ii Study

2014-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a41b8b17-dfef-5d85-8856-a9af37cc845c
DOI
10.1093/annonc/mdu438.47
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neratinib (N) with or Without Temsirolimus (Tem) in Patients (Pts) with Non-Small Cell Lung Cancer (Nsclc) Carrying Her2 Somatic Mutations: an International Randomized Phase Ii StudyDOI 10.1093/annonc/mdu438.47
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.Semantic proximity
Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Semantic proximity
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.Semantic proximity
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Semantic proximity
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.Semantic proximity
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.Semantic proximity
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.Semantic proximity
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.Semantic proximity
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.Semantic proximity
Select a neighboring publication to make it the new centre.